XT-150

Phase 1Biologic

XXalud Therapeutics, Inc.

XT-150 is one of 60 biologic programs targeting Neuropathic Pain. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Neuropathic PainActive, not recruiting

OsteoarthritisActive, not recruiting

Neuropathic PainPhase 1

Active, not recruiting

OsteoarthritisPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

778 competitors in Osteoarthritis

#DrugCompanyPhaseTrials

Ilaris

Novartis

Preclinical

2 2

Voltaren

CCerimon Pharmaceuticals

Preclinical

4 3

Cataflam

Bayer Aspirin

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

1 6

Protonix

WWyeth-Lederle Vaccines

Preclinical

1 7

Catapres

Boehringer Ingelheim

Preclinical

1 8

Benadryl

SGLT2 Inhibitor

1 10

Western Medicine

PPeking Union Medical College Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Not yet recruiting

ALS

NCT06704347

Clinical

Trials by Indication[1]

Osteoarthritis3 trials

Preliminary Safety and Efficacy of XT-150 in Facet Joint Osteoarthritis

Withdrawn·XXalud Therapeutics, Inc.·Phase 1/2·NCT04841512

Efficacy and Safety of XT-150 in Osteoarthritis of the Knee

Completed·XXalud Therapeutics, Inc.·Phase 2·NCT04124042·289 enrolled

Safety and Efficacy of XT-150 for Facet Joint Osteoarthritis Pain

Completed·XXalud Therapeutics, Inc.·Phase 2·NCT05196919·75 enrolled

Treatment2 trials

Preliminary Evaluation of Safety, Tolerability, and Efficacy of XT-150 for the Treatment of Osteoarthritic Pain

Completed·XXalud Therapeutics, Inc.·Phase 1·NCT03282149·24 enrolled

Safety, Tolerability, and Efficacy of XT-150 for the Treatment of Osteoarthritic Pain

Completed·XXalud Therapeutics, Inc.·Phase 1·NCT03477487·32 enrolled

Neuropathic Pain1 trial

Safety and Efficacy of XT-150 for Treatment of Neuropathic Pain

Terminated·XXalud Therapeutics, Inc.·Phase 1·NCT04466410·5 enrolled

ALS1 trial

Safety Study of XT-150 in Participants With ALS

Not yet recruiting·XXalud Therapeutics, Inc.·Phase 1·NCT06704347·8 enrolled

Unspecified1 trial

Follow on Extension of XT-150-1-0201

Completed·XXalud Therapeutics, Inc.·Phase 1·NCT03769662·16 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for XT-150. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — XT-150 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for XT-150. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Xalud Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: XXalud Therapeutics, Inc.

XT-150

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Osteoarthritis3 trials

Treatment2 trials

Neuropathic Pain1 trial

ALS1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News